A Combination Therapy In Patients With Social Anxiety Disorder

Phase 2

Completed

• Conditions: Social Phobia

• Registration Number: NCT00403962
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)

Detailed Description

Not available

Study Timeline

• Study Start: 2004-11
• Study Completion: 2005-08
• Study First Submitted: 2005-08-29
• Study First Submitted QC: 2006-11-23
• Study First Posted: 2006-11-27
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-13
• Last Update Posted: 2016-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 204

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in score on a Social Anxiety Disorder rating scale following 12 weeks of treatment.

Secondary Outcome Measures

Name	Time	Method
Change in score on a number of rating scales following 12 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder.

Trial Locations

Locations (1)

GSK Investigational Site; 🇿🇦 Tygerberg, South Africa